Revenue
2024
2025
Scribe Therapeutics, Inc. (SCTX)
Price$21.17Cached quote
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | $51.2M | $27.4M |
| Research & development | $60.8M | $57.1M |
| Operating expenses | $77.2M | $70.2M |
| Operating income | −$26.1M | −$42.8M |
| Operating margin | −50.94% | −156.24% |
| EBITDA | −$18.1M | −$32.3M |
| EBITDA margin | −35.45% | −117.79% |
| Net income | −$23.6M | −$37.6M |
| Net profit margin | −46.14% | −137.02% |
| Diluted EPSper diluted share | -$8.98 | -$19.94 |
Owners
Reported shareholders